“We have long highlighted the importance of vector science for the progress in GT; and, we see Commissioner Gottlieb’s comments as highly supportive of our views. We again highlight REGENXBIO (Buy) (a Chardan Top Pick for 2017, and our Gene Therapy Top Pick) as the best way to play the emergence of in vivo GT, due to the company’s: (1) rights to 100+ vectors, (2) partnerships with 10 companies, (3) 25 or so internal and external product candidates, over 10 of which are in clinical development, and (4) abundance of important 2017 catalysts, which to us represent upside options.”,” the firm’s analyst commented.
RGNX has been the topic of a number of other reports. BidaskClub upgraded shares of Regenxbio from a hold rating to a buy rating in a research report on Thursday, December 7th. ValuEngine lowered shares of Regenxbio from a hold rating to a sell rating in a research report on Tuesday, November 14th. Bank of America reiterated a buy rating and set a $38.00 target price (up from $33.00) on shares of Regenxbio in a research report on Monday, October 9th. Barclays began coverage on shares of Regenxbio in a research report on Wednesday, November 22nd. They set an overweight rating and a $38.00 target price on the stock. Finally, TheStreet lowered shares of Regenxbio from a c rating to a d+ rating in a research report on Tuesday, November 28th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $42.43.
Regenxbio (NASDAQ RGNX) opened at $28.15 on Monday. Regenxbio has a 12-month low of $16.30 and a 12-month high of $36.10.
Regenxbio (NASDAQ:RGNX) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.04. Regenxbio had a negative net margin of 764.06% and a negative return on equity of 39.33%. The company had revenue of $1.34 million for the quarter. research analysts anticipate that Regenxbio will post -2.71 earnings per share for the current year.
In related news, CFO Vittal Vasista sold 5,000 shares of the stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $27.39, for a total value of $136,950.00. Following the transaction, the chief financial officer now directly owns 99,594 shares in the company, valued at $2,727,879.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Donald J. Hayden, Jr. sold 40,000 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were sold at an average price of $28.70, for a total transaction of $1,148,000.00. Following the completion of the transaction, the director now owns 20,000 shares in the company, valued at $574,000. The disclosure for this sale can be found here. Insiders sold 144,000 shares of company stock worth $4,415,296 over the last 90 days. 17.00% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Pura Vida Investments LLC lifted its holdings in Regenxbio by 17.7% in the third quarter. Pura Vida Investments LLC now owns 33,920 shares of the biotechnology company’s stock valued at $1,118,000 after buying an additional 5,100 shares during the period. Perceptive Advisors LLC lifted its holdings in Regenxbio by 5.1% in the third quarter. Perceptive Advisors LLC now owns 1,441,186 shares of the biotechnology company’s stock valued at $47,487,000 after buying an additional 70,000 shares during the period. Jane Street Group LLC acquired a new position in Regenxbio in the third quarter valued at approximately $476,000. RTW Investments LP lifted its holdings in Regenxbio by 20.9% in the third quarter. RTW Investments LP now owns 1,539,005 shares of the biotechnology company’s stock valued at $50,710,000 after buying an additional 266,235 shares during the period. Finally, Schwab Charles Investment Management Inc. lifted its holdings in Regenxbio by 25.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 122,509 shares of the biotechnology company’s stock valued at $4,037,000 after buying an additional 24,814 shares during the period. Institutional investors and hedge funds own 68.73% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Chardan Capital Reaffirms “Buy” Rating for Regenxbio (RGNX)” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2017/12/14/chardan-capital-reaffirms-buy-rating-for-regenxbio-rgnx.html.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.